Saundry R H, Savidge G F
Coagulation Research Laboratory, Rayne Institute, St. Thomas' Hospital, London, UK.
Bioseparation. 1991;2(3):177-86.
Five different guanidinium (Gu)-derivatized agarose matrices were investigated for their potential in chromatographically resolving the Factor VIII/von Willebrand complex, VIII/vWf, fibrinogen, Fg, and fibronectin, Fn, from cryoprecipitate. Using conventional NaCl gradient methodology it was found that the order of elution of specific plasma proteins, and the yield of VIII/vWf, varied with the methods used to derivatize the agarose beads. Good yields of VIII:C (generally 30-45%) were obtained with Gu-matrices prepared by bis-oxirane coupling procedures. Cryoprecipitate binding studies showed that the capacity of Gu-Sepharose 4B, prepared by isourea modification of amino-Sepharose 4B, was 36 units VIII/vWf per ml matrix. The product, depleted of both Fg and Fn, had a specific activity of 2 units VIII:C per mg total protein, (yield 100% vWf:Ag and 47% VIII:C).
研究了五种不同的胍基(Gu)衍生化琼脂糖基质从冷沉淀中色谱分离因子VIII/血管性血友病因子复合物(VIII/vWf)、纤维蛋白原(Fg)和纤连蛋白(Fn)的潜力。使用传统的氯化钠梯度方法发现,特定血浆蛋白的洗脱顺序以及VIII/vWf的产量随用于衍生化琼脂糖珠的方法而变化。通过双环氧乙烷偶联程序制备的Gu基质可获得较高产量的VIII:C(通常为30-45%)。冷沉淀结合研究表明,通过对氨基琼脂糖4B进行异脲修饰制备的Gu-琼脂糖4B,其容量为每毫升基质36单位VIII/vWf。该产物去除了Fg和Fn,每毫克总蛋白的比活性为2单位VIII:C,(vWf:Ag产量100%,VIII:C产量47%)。